HugoScore hugoscore.org

Full review

Claimable CAIHL draft report

Evidence-linked HugoScore draft report for a health AI tool that affects patients.

Back to profile Markdown source

HugoScore CAIHL Draft Report: Claimable

Status: Draft for human review Last reviewed: 2026-06-10 Review method: Public-source review of the official homepage and FAQ, about page, for-pharma partner page, and privacy policy, plus the April 2026 enterprise launch press release and credible news coverage confirmed via search; no product walkthrough, vendor interview, or independent verification of success-rate claims. Service: Claimable Vendor: Claimable, Inc. Category: Coverage appeal AI

Summary

Claimable is a patient-facing service that generates evidence-backed appeals for denied medications. Patients upload a denial notice and insurance details, answer questions about their health story, and receive a customized appeal combining personal impact, clinical evidence, and policy arguments. Claimable faxes and mails the appeal to payer decision-makers and regulators and supports escalation if the appeal fails. The service covers over 85 treatments in condition areas including migraine, rheumatology and autoimmune disease, GLP-1s, asthma, eczema, and PANS/PANDAS. The price is a flat $39.95 plus shipping, with no-cost appeals for qualifying patients funded by support partners. The company is physician-led, founded by Warris Bokhari, MD, a former Anthem and Apple Health executive.

From a CAIHL perspective, Claimable is a strategic-action tool in the clearest sense. It helps patients contest payer decisions that most people never challenge. The unresolved question is the funding layer. In April 2026 Claimable launched an enterprise patient access platform for pharma manufacturers, health systems, and access partners. Sponsors fund free appeals and receive denial analytics marketed as payer-negotiation leverage. Pharma interest in keeping patients on therapy mostly points the same direction as patient interest in winning an appeal, but it is not the same interest, and the vendor's 80 percent success-rate claim remains self-reported.

Evidence Reviewed

CAIHL Profile

  • Who does this AI serve? Patient-directed in use, with a sponsorship caveat. The consumer product serves patients fighting denials. The enterprise layer serves pharma manufacturers and health systems, who fund free appeals and buy denial analytics.
  • Can patients tell AI is involved? Yes. AI drafting is openly marketed, and the vendor says sponsored programs are disclosed during consent.
  • Can patients meaningfully choose? Yes, within limits. Use is voluntary, but a $39.95 fee applies unless sponsored, and only supported treatments are eligible.
  • Can patients correct or challenge what the AI produces? Partial. The vendor describes a human-in-the-loop flow where patients review, edit, and approve appeals before submission, with deletion and access-revocation rights. Not verified in-app.
  • Does it help patients understand or act? Yes. Appeal generation, delivery, tracking, reminders, and escalation guidance are all action support, including a published guide for what to do after a lost appeal.

Agency Interpretation

Claimable's clearest agency value is converting a right most patients never exercise into a usable process. Fewer than 1 percent of denied claims are appealed. Claimable automates the research, drafting, and delivery work that otherwise takes experienced advocates many hours, and it deliberately frames appeals around patient rights under ACA and ERISA. The FAQ on patient-led versus provider-led appeals is itself a piece of critical-reflection content about how the system works.

The unresolved CAIHL tension is who pays. Claimable's growth model is sponsorship by pharma manufacturers and health systems, and its pharma page markets aggregated appeals data as contract-negotiation leverage and brand-level support analytics. That funding expands free access, and the vendor says sponsorship is disclosed at consent. But it means the tool's economics reward appeals for sponsored drugs, and patients should be able to see clearly when their appeal is also serving a manufacturer's market-access strategy. The 80 percent win rate should be treated as a marketing claim until independently audited.

Key Unknowns

  • Whether the 80 percent success rate and 10-day resolution claims hold up under independent or per-condition scrutiny.
  • How patients are informed, in practice, when an appeal is sponsor-funded, and how prominent that disclosure is.
  • Whether unsponsored conditions and medications receive equal product attention over time.
  • What specific data fields flow into pharma-facing analytics dashboards and how de-identification is performed.
  • Retention periods for appeal documents and medical records, which the privacy policy defines only by criteria.
  • What happens to patients whose appeals fail beyond written guidance, including whether escalation support is included in the flat fee.
  • Language access, disability access, and support for patients without reliable internet.

Publication Recommendation

Ready for human review as a draft profile. Confidence should stay at medium until success-rate claims are independently checked, the sponsorship disclosure flow is verified in-product, and pharma-facing data flows are documented in more detail. The sponsorship-alignment caveat should remain in the public summary even if the profile is later upgraded.